Skip to content
Calculator
Guide

NAD+ injections are not peptides: what NAD+ is and what the trials show

Last updated: October 27, 2026 · 8 min read · By the Grey Peptides Editorial Board

Close-up image of an IV drip and hand in a hospital room, illustrating medical care
Photo by RDNE Stock project on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • NAD+ is not a peptide. It is a coenzyme built from two nucleotides, with no amino acids, and our encyclopedia classes it as a small molecule.
  • Oral NAD+ precursors (NR and NMN) reliably raise NAD-related metabolites and are well tolerated, but across 33 human intervention studies their effects on health outcomes were heterogeneous and often null.
  • A 2026 systematic review found no outcome trial of IV or injected NAD+ for anti-ageing or wellness. In a retrospective review of a wellness company's clients, IV NAD+ caused moderate to severe gastrointestinal symptoms, faster heart rate and chest pressure during infusion.

What NAD+ actually is

Nicotinamide adenine dinucleotide, NAD+, is one of the most important small molecules in every cell. It is a cofactor for oxidative phosphorylation and ATP production, and a substrate for signalling enzymes including sirtuins and the PARPs involved in DNA repair 1 2. A 2018 review describes NAD+ as a redox carrier and signalling molecule controlling hundreds of processes, rising and falling with food intake, exercise and time of day, and declining with age 3. A 2019 review adds that NAD+ is depleted by PARP activation after DNA damage and by the enzyme CD38 during chronic inflammation 1.

Chemically, NAD+ is two nucleotides joined through their phosphate groups: one carrying nicotinamide, a form of vitamin B3, and one carrying adenine. It contains no amino acids, and our encyclopedia classes it as a small molecule, not a peptide 4.

A peptide (e.g. BPC-157)NAD+
Built fromAmino acids joined by peptide bondsTwo nucleotides joined by a phosphate bridge
Contains amino acids?YesNo
Role in the bodySignalling molecules, hormones, fragments of proteinsA coenzyme in energy metabolism and a substrate for enzymes such as sirtuins and PARPs
Our molecule classPeptideSmall molecule

Why it is sold as if it were a peptide

Commercial clinical and wellness settings increasingly provide intravenous NAD+ despite limited evaluation of its safety and effectiveness, as the authors of a 2026 tolerability study put it 5, and it turns up in the same 'longevity' conversations as research peptides. Our encyclopedia carries an NAD+ entry for that reason, with a note that it is a coenzyme, not a peptide 4. Our guide to what makes a peptide explains the definitions, and why compounds such as MK-677 and orforglipron are discussed as peptides too, although they are not 4.

The difference matters because the evidence and the rules differ. NAD+ precursors have been tested in 33 human intervention studies 6; intravenous NAD+ raises its own questions, quite separate from peptide injections.

Why the excitement started: the animal work

Interest in NAD+ for ageing comes from a large animal literature. The 2018 review summarises it: NAD+ declines with age, and restoring it in old or diseased animals can improve health and extend lifespan, which prompted the search for safe NAD-boosting molecules 3. Specific studies show the range. In mice on a high-fat diet, nicotinamide riboside reduced weight gain, fatty liver, inflammation and insulin resistance, an effect that depended on the exercise hormone irisin; NR also raised irisin in human volunteers 7. In mice with acute metabolic acidosis, the precursor nicotinamide strongly protected kidney tubules 8, and in mice and piglets with acute kidney injury, ultrasound-responsive liposomes that drove NAD+ synthesis in kidney cells helped damaged mitochondria recover and prevented kidney damage 9.

The 2026 systematic review found the same pattern across 80 rodent studies: improvements in metabolic, mitochondrial, inflammatory and functional outcomes were frequent but varied across models and endpoints 6. The human trials below show how much harder the step to people has been.

What the oral precursor trials show

Most human research on raising NAD+ has used precursors taken by mouth, chiefly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), rather than NAD+ itself. In a randomised, double-blind crossover trial in healthy middle-aged and older adults, six weeks of NR was well tolerated and effectively raised NAD+ metabolism, with initial hints about blood pressure and arterial stiffness that the authors said needed testing in larger trials 10. In postmenopausal women with prediabetes who were overweight or obese, ten weeks of NMN increased insulin-stimulated glucose disposal, measured with the hyperinsulinaemic-euglycaemic clamp, and muscle insulin signalling, against no change on placebo 11. In 30 people newly diagnosed with Parkinson's disease, 30 days of NR raised brain NAD+ levels variably, and those whose levels rose showed changes in brain metabolism associated with mild clinical improvement 12.

The wider picture is more sobering. A 2026 systematic review of 113 studies, 33 of them human intervention studies (28 randomised), found that oral NR and NMN consistently raised NAD-related metabolites and were well tolerated over weeks to months, but that effects on functional, metabolic, vascular and other healthspan outcomes were heterogeneous and often null 6. In other words, the precursors reliably do what they are supposed to do chemically, and much less reliably do anything that a person would notice or that matters for health.

What happens to NAD+ precursors in the body

Part of the explanation may be what happens after a dose, and the mouse studies do not agree on the details. In a 2025 mouse study, only a small part of oral NMN or NR was absorbed intact; most was converted by gut bacteria to nicotinic acid, and given intravenously, NMN and NR were rapidly broken down to nicotinamide and secreted into bile, then converted by gut bacteria 13. Earlier isotope-tracing work in mice found that tissues differ widely in how fast they make and consume NAD+, that oral NR or NMN were metabolised to nicotinamide in the liver, but that intravenous NR or NMN did deliver intact molecules to multiple tissues 2. Either way, an oral precursor mostly does not reach tissues as itself.

IV NAD+: the evidence gap

Intravenous and injected NAD+ is what clinics sell most aggressively, and it is where the evidence is thinnest. The 2026 systematic review found no eligible outcome trials of intravenous or intramuscular NAD+ itself for anti-ageing or wellness; one intravenous NAD+ pharmacokinetic pilot had no clinical outcomes 6.

What exists is a trial in a specific disease and clinic data on tolerability. In a single-centre randomised, placebo-controlled trial of 180 adults with ischaemic cardiomyopathy (published online in September 2025), a seven-day course of intravenous NAD+ alongside guideline-directed treatment left ejection fraction higher at one month (45.4% against 42.4%, p = 0.024), with non-significant trends towards fewer heart failure hospitalisations at six months 14. That is a single trial in heart failure, not evidence for wellness drips, and its secondary measures did not reach statistical significance. A retrospective review of commercial clients given four consecutive daily infusions of NAD+ or NR, written by researchers at the wellness company that gave them, found that NAD+ caused moderate to severe gastrointestinal symptoms, faster heart rate and chest pressure during infusion, which stretched infusion times to an average of 97 minutes against 37 for NR; symptoms resolved after infusion, and liver, kidney and inflammation markers did not change 5.

Regulatory status

NAD+ is not approved by FDA for any use 4. FDA's 503A bulk drug substances list, updated May 14, 2026, places nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide disodium reduced (NADH) in Category 1, bulk drug substances under evaluation, while beta-nicotinamide adenine dinucleotide disodium salt trihydrate is in Category 3, nominated without adequate support 15. Our entry records that FDA's interim policy does not act against pharmacy compounding from Category 1 substances while they are under evaluation; that is not an approval 4. The precursor NR is sold as a dietary supplement 4.

For athletes: the infusion rule

NAD+ itself is not named on WADA's Prohibited List, and our entry records its status under S0 as unsettled 4. But the method matters. WADA's 2026 List prohibits "intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations" (M2.2) 16. An infusion above that volume is a prohibited method whatever is in the bag, so a tested athlete needs to know the volume before any drip.

Questions to ask before an NAD+ drip

  • What outcome is this meant to improve, and has a randomised trial of IV NAD+ shown that it does? (For wellness and anti-ageing, a 2026 systematic review found no such outcome trial.)
  • Where is the NAD+ from, and is it compounded by a licensed pharmacy?
  • How large is the infusion, how long will it take, and what happens if I feel nauseous, flushed or develop chest pressure?
  • If I am a tested athlete, is the total volume above 100 mL in 12 hours?
  • Would an oral precursor, which has more trial data, serve the same purpose, and is there any reason to take either?

Where NAD+ fits with the mitochondrial peptides

NAD+ is often discussed together with mitochondria-derived peptides such as MOTS-c and humanin. They are entirely different molecules with different evidence: our MOTS-c and humanin entries find human studies that only measured the body's own levels, with none giving either peptide as a treatment, while NAD+ precursors have 33 human intervention studies with often null results 6. Our article on humanin and the SHLPs covers the peptides. We found no trial of NAD+ combined with either.

The bottom line

As of October 27, 2026, NAD+ is a coenzyme, not a peptide. Raising it with oral precursors works biochemically and is well tolerated, but benefits for health outcomes in people have been inconsistent. Intravenous NAD+ for anti-ageing or wellness has no outcome trials, caused uncomfortable symptoms during infusion in the one tolerability study, and any infusion over 100 mL in 12 hours breaks anti-doping rules outside hospital care. One trial in heart failure showed a modest one-month gain in ejection fraction. Nothing here is advice or a dose.

Frequently asked questions

Is NAD+ a peptide?

No. NAD+ is a coenzyme made of two nucleotides and contains no amino acids. It is often discussed alongside peptides, but it is a small molecule.

Do NAD+ injections work?

No outcome trial supports IV or injected NAD+ for anti-ageing or wellness. A randomised trial in ischaemic heart failure found a higher ejection fraction at one month on IV NAD+ than placebo; that is a specific disease, not general wellness.

NMN vs NR: which raises NAD+?

Both raise NAD-related metabolites when taken by mouth and are generally well tolerated, but across 33 human intervention studies their effects on health outcomes were heterogeneous and often null.

What are the side effects of an NAD+ drip?

In a retrospective review of a wellness company's clients, IV NAD+ caused moderate to severe gastrointestinal symptoms, faster heart rate and chest pressure during infusion, which resolved afterwards but lengthened infusions to an average of 97 minutes.

Sources

  1. Braidy, N., et al. (2019). Role of Nicotinamide Adenine Dinucleotide and Related Precursors as Therapeutic Targets for Age-Related Degenerative Diseases: Rationale, Biochemistry, Pharmacokinetics, and Outcomes. Antioxid Redox Signal, 30(2), 251-294. PMID: 29634344
  2. Liu, L., et al. (2018). Quantitative Analysis of NAD Synthesis-Breakdown Fluxes. Cell Metab, 27(5), 1067-1080.e5. PMID: 29685734
  3. Rajman, L., et al. (2018). Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab, 27(3), 529-547. PMID: 29514064
  4. Grey Peptides encyclopedia entry for NAD+: molecule class (small molecule), not FDA-approved, supplement status of nicotinamide riboside, WADA status unsettled; molecule classes for MK-677 and orforglipron. Re-read October 27, 2026.
  5. Reyna, K., et al. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD(+)) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging, 7, 1652582. PMID: 41704678
  6. Gallagher, C., et al. (2026). NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev, 116, 103057. PMID: 41655607
  7. Li, D. J., et al. (2021). NAD(+)-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin. Theranostics, 11(9), 4381-4402. PMID: 33754067
  8. Bugarski, M., et al. (2021). Changes in NAD and Lipid Metabolism Drive Acidosis-Induced Acute Kidney Injury. J Am Soc Nephrol, 32(2), 342-356. PMID: 33478973
  9. Lei, Y., et al. (2025). NAD(+) biosynthesis and mitochondrial repair in acute kidney injury via ultrasound-responsive thylakoid-integrating liposomes. Nat Biomed Eng, 9(10), 1740-1757. PMID: 40461655
  10. Martens, C. R., et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults. Nat Commun, 9(1), 1286. PMID: 29599478
  11. Yoshino, M., et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224-1229. PMID: 33888596
  12. Brakedal, B., et al. (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab, 34(3), 396-407.e6. PMID: 35235774
  13. Yaku, K., et al. (2025). Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD(+) synthesis via enterohepatic circulation. Sci Adv, 11(12), eadr1538. PMID: 40117359
  14. Yu, X., et al. (2026). Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial. Am J Cardiovasc Drugs, 26(1), 97-106. PMID: 40954388
  15. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (Categories 1 to 3). Updated May 14, 2026; re-read October 27, 2026. FDA
  16. World Anti-Doping Agency. The 2026 Prohibited List, in force January 1, 2026, M2.2 (intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period, except in hospital treatment, surgery or clinical diagnostic investigations). M2.2 re-read October 27, 2026. WADA

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead